Observational studyPreclinical

Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

Inflammatory bowel diseases, 2008 Mar. Kannengiesser K, Maaser C, Heidemann J and 7 others.

Study type

Observational study

Subjects

Animal / preclinical (no Humans MeSH term)

Journal

Inflammatory bowel diseases

Published

2008 Mar

PubMed

PMID 18092346 ↗

DOI

10.1002/ibd.20334 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

KPV →glow klow healing blends evidence →

Indexed under

MeSH terms assigned by the National Library of Medicine.

AnimalsColonDextran SulfateDisease Models, AnimalHormonesInflammatory Bowel DiseasesIntestinal MucosaLeukocyte Common AntigensMiceMice, Inbred C57BLPeroxidaseReceptor, Melanocortin, Type 1

Other papers on KPV

Review · 2008

Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases

Journal article · 2008

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

Journal article · 2003

Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page